You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 11, NOVEMBER 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Hepatitis C Virus Seroprevalence in the Developmentally Disabled

William M. Levinson, MD; Gary P. Wormser, MD; Gilda Forseter, RN; Mark Calmann, MPA; Thomas A. O'Brien, PhD

Arch Intern Med. 1992;152(11):2309-2311.


Abstract

Background.—
Hepatitis C virus (HCV) is the principal cause of nonenteric non-A, non-B hepatitis worldwide. While it has been well documented that people with developmental disabilities are at an increased risk for infections with hepatitis B virus, little is known of the prevalence of HCV infection among this population.

Methods.—
Serum samples obtained from 113 evaluable outpatients with developmental disabilities at one center in suburban New York City (NY) were tested for antibodies to HCV and hepatitis B core antibody.

Results.—
None of the 113 samples tested positive for HCV antibody by enzyme-linked immunosorbent assay, whereas 24 (21%) showed serologic evidence of past hepatitis B virus infection on the basis of hepatitis B core antibody positivity. Three (2.7%) were also positive for hepatitis B surface antigen.

Conclusions.—
In contrast to hepatitis B virus, HCV infection is uncommon among outpatients with developmental disabilities in suburban New York City. Further testing for HCV is indicated to determine if these results can be generalized to individuals within institutions, or to individuals in other geographic locations.

(Arch Intern Med. 1992;152:2309-2311)



Author Affiliations

From the Section of Developmental Pediatrics, Department of Pediatrics (Dr Levinson) and Division of Infectious Diseases, Department of Medicine (Dr Wormser and Ms Forseter), New York Medical College, Valhalla; and Ortho Diagnostic Systems Inc, Raritan, NJ (Mr Calmann and Dr O'Brien).


Footnotes

Accepted for publication March 20, 1992.

Reprint requests to Westchester County Medical Center, Cedarwood Hall, Room 216, Valhalla, NY 10595-1689 (Dr Levinson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.